European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update

Table 5 Randomized placebo-controlled phase II and III clinical trials in individuals with chronic migraine

Drug/Trial	Phase	Dose	Duration	№ of participants
Eptinezumab
NCT02275117 [20]	IIb	100 mg (q) 300 mg (q)	12 weeks	364
PROMISE-2 NCT02974153 [22]	III	100 mg (q) 300 mg (q)	12 weeks	1121
Erenumab
NCT02066415 [19]	II	70 mg (m) 140 mg (m)	12 weeks	667
NCT03812224 [29]	III	70 mg (m)	24 weeks	261
Fremanezumab^a
NCT02021773 [17]	II	225 mg (m + 675 mg ld)	12 weeks	177
HALO CM NCT02621931 [13]	III	225 mg (m + 675 mg ld) 675 mg (q)	12 weeks	1130
NCT03303079 [27]	III	225 mg (m + 675 mg ld) 675 mg (q)	12 weeks	571
FOCUS NCT03308968 [11]	IIIb	225 mg (m + 675 mg ld) 675 mg (q)	12 weeks	509
Galcanezumab
REGAIN NCT02614261 [23]	III	120 mg (m + 240 mg ld)	12 weeks	836
CONQUER NCT03559257 [8]	IIIb	120 mg (m + 240 mg ld)	12 weeks	193

Duration of all the studies is expressed in weeks and transformed as appropriate from the original study
(m) indicates monthly, (q) indicates quarterly, ld indicates loading dose
^aThe 675 mg loading dose did not enter clinical practice; however, it was tested in all trials of the 225 mg monthly dose. The difference between trials tested dose and clinical practice dosing was considered in the evaluation of quality of evidence and lead to a downgrade

ISSN: 1129-2377